Granite Bio AG

The funded studies reflect an interest in immunological mechanisms linked to bowel inflammation, including evaluation of treatment effects on disease-related biological responses in ulcerative colitis.

• Immunology
• Inflammatory disease biology
• Pharmacodynamics

Research activity includes work in both healthy volunteers and patients, supporting investigation of how the therapy interacts with inflammatory pathways.

Granite Bio AG is involved in early clinical evaluation of GRT-001, with attention to safety, tolerability, and pharmacokinetics in healthy subjects and individuals with ulcerative colitis.

• Safety assessment
• Tolerability
• Pharmacokinetics

The clinical portfolio includes both single-dose and multiple-dose administration research, indicating a focus on foundational therapeutic characterization.

One research stream examines subcutaneous administration of GRT-001, with clinical interest in how this route supports exposure assessment and treatment development in healthy volunteers.

• Subcutaneous delivery
• Healthy volunteers
• Exposure evaluation

This area complements the sponsor’s work in gastroenterology by extending investigation into practical administration approaches for an inflammatory disease therapy.